, Columnist
Pfizer's Murky Post-Allergan Path
Its other options, including straight M&A, have drawbacks, too, though.
This article is for subscribers only.
Underestimate Fightin' Jack Lew and his Treasury Department at your peril.
Pfizer and Allergan have been acting as if their $160 billion merger was a sure thing, despite the fact that the deal -- designed in part to net Pfizer a lower Irish tax rate -- pretty clearly stuck in the craw of the Obama administration.